Research & Development

Clinical studies 

Dilafor is currently carrying out a phase IIb clinical trial in Sweden and Finland within the indication labor arrest. The study is a randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the effects of continuous infusion of tafoxiparin as an adjunct treatment to oxytocin for up to 36 hours in term pregnant, nulliparous women in order to treat primary slow progress of labor including prolonged latent phase and primary labor arrest. In total, 360 pregnant women are planned to be enrolled in the study. For further information on the study and participating clinical sites, please see:

In 2009, an exploratory Proof of Concept phase II clinical study, comprising a total of 263 women, was completed.Tafoxiparin was shown to be safe and well tolerated, and analyses of the results indicate that treatment with tafoxiparin can provide beneficial effects in women induced into labor and women with need of oxytocin due to labor arrestor primary slow progress of labor. Most importantly, the results of the study gave Dilafor a solid base with which to plan in detail the further and ongoing clinical development program for a number of indications within the obstetric field. For further information on the study, please see:

In 2015 and 2016,Dilafor performed and finalized additional phase I studies in Europe and Asia.The phase I studies were focused on the evaluation of the safety and pharmacokinetics of tafoxiparin using a multidosing schedule of tafoxiparin.The study demonstrated tafoxiparin to be safe and well tolerated and with a predictive pharmacokinetic profile. The outcomes of the studies were used in the planning of the global clinical trial program in two major indications: labor induction and labor arrest.

“I am delighted that my 40 years’ preclinical and clinical research have reached this significant milestone. There is a great medical need for new treatments to address protracted labor and I hope that tafoxiparin will make a difference for all these pregnant women.”

Professor Gunvor Ekman Ordeberg, Founder and CMO at start of phase IIb